MilliporeSigma Webinars
-
Accelerate Your AAV Journey To IND And Beyond
6/26/2025
Explore essential QC strategies in AAV gene therapy and learn how to address rcAAV detection, viral clearance per ICH Q5A, and impurity profiling using NGS to meet evolving regulatory demands.
-
Purity As A Priority: Optimizing Safety Measures For rAAV Therapies
2/11/2025
Watch to learn how rAAV vectors in gene therapy are addressing manufacturing impurities, risks to patient safety, and analytical methods for detection while aiding sponsors in regulatory compliance.
-
How To Prevent Protein Aggregation Through Stabilizers And Surfactants
1/13/2025
Learn about protein aggregation mechanisms, the role of excipients in stabilization, and novel surfactants that prevent aggregation in therapeutic protein formulations in this webinar.
-
Nitrosamines - New Requirements To Evaluate Contamination Risks
12/23/2024
Explore nitrosamine contamination, regulatory actions, and new evaluation requirements, featuring expert insights from Dr. Ulrich Reichert on prevention and risk assessment strategies.
-
BioPhorum Raw Materials Risk Assessments
12/19/2024
Torsten Schaderdorf provides an in-depth exploration of current regulations related to Raw Materials Risk Assessment, highlighting the risk criteria and raw material scope outlined in the BioPhorum guidelines.
-
Assemblies Are Not Particulate Free, Strategies For Risk Mitigation
12/19/2024
As single-use technologies gain prominence in critical applications, the scrutiny around particulate contamination intensifies due to its potential impact on drug product quality, safety, and patient outcomes.
-
Transforming The Biopharma Supply Chain, eData Solutions For Agility And Manufacturing Efficiency
12/19/2024
Explore the role of eData in automating processes, enabling predictive analytics, improving supply chain resilience, and adopting standardized digital platforms in biopharma manufacturing.
-
Managing Nitrite Impurities: Supplier-Manufacturer View
12/19/2024
Examine nitrites in excipients, nitrosamine risks, regulatory considerations, analytical controls, and a case study on mitigating risks in pharmaceutical manufacturing and storage.
-
How Standardized Extractables Data Support E&L Risk Assessment
12/19/2024
Explore E&L evaluations, USP <665>, supplier-provided extractables data, and collaborative strategies to mitigate risks in Single-Use Systems for biopharmaceutical manufacturing processes.
-
Evaluating USP 665 For Extractables Testing And Reducing Animal Testing For Biological Reactivity
12/19/2024
Explore evolving compendial methods, USP <665>, and transitioning to cell-based assays for extractables, leachables, and biological reactivity in single-use pharmaceutical manufacturing.